Secondary acute myeloid leukemia and early infection are independent predictors of poor survival in acute myeloid leukemia treated with hypomethylating agents and venetoclax

Affiliations

¹ Section of Hematology, Department of Medical and Surgical Sciences, Azienda Ospedaliero-Universitaria di Modena, University of Modena and Reggio Emilia, Modena, Italy.
² Division of Hematology, ASUGI, Trieste, Italy.
³ Division of Hematology, Ospedale Vito Fazzi, Lecce, Italy.
⁴ Division of Hematology and Stem Cell Transplantation, ASUFC, University of Udine, Udine, Italy.
⁵ Section of Hematology, Spedali Civili, Brescia, Italy.
⁶ U.O. Oncoematologia, Fondazione IRCCS Ca' Granda OspedaleMaggiore Policlinico, University of Milan, Milan, Italy.
⁷ Division of Hematology, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
⁸ Division of Hematology, Polo Onco-Ematologico, Fondazione Policlinico A. Gemelli-IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.

Stefano Cordella et al. Hematol Oncol. 2024 Sep.

. 2024 Sep;42(5):e3310.

doi: 10.1002/hon.3310.

¹ Section of Hematology, Department of Medical and Surgical Sciences, Azienda Ospedaliero-Universitaria di Modena, University of Modena and Reggio Emilia, Modena, Italy.
² Division of Hematology, ASUGI, Trieste, Italy.
³ Division of Hematology, Ospedale Vito Fazzi, Lecce, Italy.
⁴ Division of Hematology and Stem Cell Transplantation, ASUFC, University of Udine, Udine, Italy.
⁵ Section of Hematology, Spedali Civili, Brescia, Italy.
⁶ U.O. Oncoematologia, Fondazione IRCCS Ca' Granda OspedaleMaggiore Policlinico, University of Milan, Milan, Italy.
⁷ Division of Hematology, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
⁸ Division of Hematology, Polo Onco-Ematologico, Fondazione Policlinico A. Gemelli-IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.

No abstract available

References

1. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and Venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617‐629. https://doi.org/10.1056/NEJMoa2012971
1. Pratz KW, Jonas BA, Pullarkat V, et al. Long‐term follow‐up of VIALE‐A: venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia. Am J Hematol. 2024;99(4):615‐624. https://doi.org/10.1002/ajh.27246
1. Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345‐1377. https://doi.org/10.1182/blood.2022016867
1. Ucciero A, Pagnoni F, Scotti L, et al. Venetoclax with hypomethylating agents in newly diagnosed acute myeloid leukemia: a systematic review and meta‐analysis of survival data from real‐world studies. Cancers. 2023;15(18):4618. Published 2023 Sep 18. https://doi.org/10.3390/cancers15184618
1. Candoni A, Lazzarotto D, Papayannidis C, et al. Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first‐line therapy with hypomethylating agents alone or in combination with Venetoclax. Am J Hematol. 2023;98(4):E80‐E83. https://doi.org/10.1002/ajh.26846